Incyte (INCY)
Health Care · Biotechnology · NASDAQ
Incyte is a biopharmaceutical company focused on discovering and developing innovative medicines for oncology and inflammatory conditions.
What Incyte does
Incyte is a global biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The company specializes in oncology and inflammatory diseases, with a portfolio that includes approved treatments and a pipeline of clinical-stage candidates. It generates revenue primarily through product sales and royalty arrangements.
Themes: oncology, inflammatory diseases, dermatology, targeted therapies, drug discovery and development
Fundamentals
- Price$127.81 as of 2026-08-21 close
- Market cap$25.5B as of 2026-08-21
- 1-year return+47.7% 2025-08-21 close $86.53 → 2026-08-21 close $127.81
- P/E15.14 as of 2026-08-24
- Net margin+27.7% as of 2026-08-24
- Gross margin+93.1% as of 2026-08-24
- ROE+29.6% as of 2026-08-24
- Debt / equity0.01 as of 2026-08-24
- Revenue growth (YoY)+26.9% as of 2026-08-24
- Revenue CAGR (3y)+14.8% SEC XBRL
- Beta0.74 as of 2026-08-24
- Last reported earnings2026-07-28 SEC EDGAR Form 8-K (Item 2.02)
How INCY compares in its sector
- price-to-earnings ratiobottom 25% 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 10% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 10% 504 covered Health Care peers, as of 2026-08-24
- gross margintop 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
INCY is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
65.8 #38 of 1,704 scored · #15 of 240 in Health Care
Trend 78th: a "golden cross" — its 50-day average is above its 200-day; catalysts 77th: open-market insider buys in 90 days 70, analysts have raised their average price target by 0.9% since the prior reading; weakest is volume and participation 45th: trading volume is about normal versus its 30-day average.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How Incyte looks technically
Incyte (INCY) is trading 23.4% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 265 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 23 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 65, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive). It made a new 20-day high about 19 trading days ago. It is 3.6% below its 52-week high (its highest price of the past year).
Trend
8
| Distance from the 200-day | it is trading 23.4% above its 200-day average, the long-term trend line — a longer-term uptrend | +23.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $116.17 | $116.17 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $103.54 | $103.54 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 115.77. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 265 trading days ago — a "golden cross", a bullish long-term signal | 265 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 23 (a reading of 25+ marks a strong trend) | 22.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 65, neither overbought (above 70) nor oversold (below 30) | 65.4 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($115.77 to $129.92) — its "stochastic" reading is 85 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 85.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive) | 3 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $132.58 | $132.58 |
|---|---|---|
| From the 52-week high | it is 3.6% below its 52-week high (its highest price of the past year) | -3.6% |
| Above the 52-week low | it is 57.6% above its 52-week low (its lowest price of the past year) | +57.6% |
| Below the 52-week high | it is 3.6% below its highest point of the past year | 3.6% |
| Since a 20-day breakout | it made a new 20-day high about 19 trading days ago | 19 sessions |
| Since a 55-day breakout | it made a new 55-day high about 19 trading days ago | 19 sessions |
| All-time high | its highest closing price on record is $153.15 (set on 2017-03-15) | $153.15 |
| Given back of the 52-week move | over the past year its closes ranged ($81.66 to $129.93), and it has given back only a small part of its rise from last year’s low — 4% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $98.55 to $100.10. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 4.4% |
| From the all-time high | it is 16.5% below its all-time high | -16.6% |
| Nearest price level | it is trading 6.7% above a support level at $119.28 — a price it turned at twice since 2026-07-09, most recently on 2026-07-17. Since 2024-08-21 it has 15 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -6.7% |
| All-time low | its lowest closing price on record is $1.85 (set on 2008-11-21) | $1.85 |
| Above the all-time low | it is 6808.6% above its all-time low | +6,809% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 60th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $3.75 between its high and its low — about 2.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $3.75 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $115.46 and $129.61 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $115.46 – $122.54 – $129.61 |
| Typical daily range (% of price) | its price moves about 2.9% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.9% |
| Stretch from the 200-day average | it is trading 6.5 daily ranges above its 200-day average price (23.4% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.5 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.79× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.9% since the prior reading | +0.9% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a bullish engulfing | today it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | today |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.6% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.6% |
|---|---|---|
| Open gap | it gapped 2.3% above the previous close 39 sessions ago and has not traded back through the level it left behind at 107.53 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.3% |
| Gap filled | a 2.8% gap up opened on 2026-08-05 has been "filled" 12 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 12 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 6.5 percentage points (the stock gained 8.9% while the market gained 2.3%) | +6.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 28.1 percentage points (the stock gained 31.2% while the market gained 3.1%) | +28.1% |
| vs market, 6 months | over the past 6 months this stock beat the market by 15.1 percentage points (the stock gained 26.1% while the market gained 11.1%) | +15.1% |
| vs market, 12 months | over the past 12 months this stock beat the market by 27.2 percentage points (the stock gained 47.7% while the market gained 20.5%) | +27.2% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 15% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 4.4% of the share price. | +15.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 22% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $104.87 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +21.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% above the average price paid since it last reported on 2026-07-28 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $123.74 — a volume-weighted average of daily closes over 19 sessions, not a true tick-by-tick VWAP. | +3.3% |
Price levels it has turned at before
INCY last closed at $127.81 on 2026-08-21. Since 2024-08-21 it has turned at 15 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $119.28 | Support | 6.7% below the last close | turned there twice · 2026-07-09 to 2026-07-17 |
| $108.92 | Support | 14.8% below the last close | turned there five times · 2025-11-12 to 2026-06-11 |
| $103.11 | Support | 19.3% below the last close | turned there three times · 2025-12-19 to 2026-05-11 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $115.77.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $137.79 and $151.40 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $115.77.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · MACD just crossed bullish (12/26/9) · beating the market · Printed a bullish engulfing pair · Stretched far above its 200-day average (6+ daily ranges) · At the top of its 14-day range (stochastic above 80) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.33 mean, 1=Strong Buy…5=Strong Sell) — 23 analysts
- Mean price target$126.04 range $86.00 – $155.00; median $125.00
Analyst estimates, as of 2026-08-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for INCY
- Consensus EPS estimate-$3.44 next reporting period, as of 2026-08-21
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on the success and commercialization of a limited number of core products.","Substantial risks associated with the clinical trial process, including potential for failure or delays in development.","Intense competition in the biopharmaceutical industry from established companies with greater resources."]
What changed in the latest 10-Q
AI-assisted comparison of INCY's 10-Q filed 2026-04-28 against the prior one filed 2025-10-28.
Management's Discussion & Analysis (MD&A)
- Added:
- Added reference to 'year ended December 31, 2025' in the opening paragraph (newer filing dated 2026-04-28)
- Added 'and nature' before 'and timing of clinical trial results' in the bullet points (newer filing)
- Added 'expectations with respect to reimbursement for our products; expectations with respect to the impact on our revenues of U.S. or other government proposals regarding drug pricing' as a separate bullet point (newer filing)
- Removed 'the risk of' prefixes from multiple bullet points, converting to direct statements (newer filing)
- Removed:
- Removed reference to 'three and nine months ended September 30, 2025' from opening paragraph (older filing dated 2025-10-28)
- Removed reference to 'year ended December 31, 2024' from opening paragraph (older filing)
- Removed 'the risk of' prefix from 'civil or criminal penalties' bullet point (newer filing removes this language)
- Removed 'the risk of' prefix from 'unanticipated delays in, or discontinuations of' bullet point (newer filing)
- Removed 'the risk that' prefix from 'previous preclinical testing or clinical trial results' bullet point (newer filing)
- Removed 'risks relating to' prefix from 'the conduct of our clinical trials' bullet point (newer filing)
- Removed 'the risk of' prefix from 'adverse safety findings' bullet point (newer filing)
- Removed 'the risk that' prefix from 'results of our clinical trials do not support' bullet point (newer filing)
- Removed 'risks relating to' prefix from 'our reliance on third-party manufacturers' bullet point (newer filing)
- Removed 'risks relating to' prefix from 'the development of new products' bullet point (newer filing)
- Removed 'risks relating to' prefix from 'our ability to sustain profitability' bullet point (newer filing)
- Removed 'risks related to' prefix from 'public health pandemics' bullet point (newer filing)
- Reworded:
- Changed 'the timing of clinical trial results' to 'the nature and timing of clinical trial results' (newer filing dated 2026-04-28)
- Changed 'plans to use third-party manufacturers' to 'plans relating to the use of third-party manufacturers' (newer filing)
- Reorganized bullet point structure: older filing combined 'expected expenses and expenditure levels; expected uses of cash; expectations with respect to the need or ability to raise additional capital; expected revenues and sources of revenues; expectations with respect to inventory' into one bullet, newer filing separates this into two bullets with different wording
- Changed 'risks relating to changes in pricing and reimbursement in the markets in which we compete' to 'changes in drug pricing and reimbursement in the markets in which we or our collaborators and licensees commercialize our drug products' (newer filing)
- Changed 'the impact of technological advances and competition to develop and commercialize similar drug products' to 'the impact of technological advances and competition to develop and commercialize drug products similar to our own' (newer filing)
- Removed 'the risk of' and 'risks relating to' prefixes throughout the risks section, converting to direct statement format (newer filing vs. older filing)
- Notes:
- The newer filing was truncated mid-sentence at the end ('except where it is made clear that such term means only the pa'), preventing full assessment of the complete closing text
- The older filing was also truncated at the end ('Incyte, JAKAFI, MINJUVI, MONJUVI, OPZELURA,'), preventing assessment of any final additions or removals
- Text formatting and presentation differ between filings but substantive content comparisons are based on the actual language changes present
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 19 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 15 sells ($9M) — 2 selling insiders
- Last 90 days0 buys · 19 sells ($13M) — 5 selling insiders
- Last 180 days0 buys · 22 sells ($16M) — 6 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-05. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about INCY's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 1 matched disclosure for INCY from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding INCY as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 33,709,984
- Reported value $3,172,783,646
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 1 increased, 5 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
INCY had 10,246,477 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
INCY had 5.13% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.8 days to cover at the same settlement.
- Reported short interest (shares) 10,246,477
- Short interest (% of shares outstanding) 5.13%
- Prior settlement (shares) 10,512,123
- Reported change -2.53%
- Days to cover (reported) 4.8
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Novartis (NVS)
- Bristol Myers Squibb (BMY)
- Eli Lilly (LLY)
- AstraZeneca (AZN)
- AbbVie (ABBV)
- Amgen (AMGN)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare INCY vs…
Incyte is found in…
Frequently asked questions
What does Incyte (INCY) do?
Incyte is a global biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The company specializes in oncology and inflammatory diseases, with a portfolio that includes approved treatments and a pipeline of clinical-stage candidates. It generates revenue primarily through product sales and royalty arrangements.
What sector is Incyte (INCY) in?
Incyte (INCY) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are Incyte's (INCY) competitors?
Notable peers of Incyte (INCY) include Novartis, Bristol Myers Squibb, Eli Lilly, AstraZeneca and AbbVie. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in INCY?
Yes — we hold 1 matched STOCK Act disclosure for INCY from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Incyte (INCY) overbought or oversold right now?
Incyte (INCY) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 65, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on INCY come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.